<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676117</url>
  </required_header>
  <id_info>
    <org_study_id>D961HC00007</org_study_id>
    <nct_id>NCT00676117</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males</brief_title>
  <official_title>A Single-Centre, Open, Randomised, Three-Way Cross-Over Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic profile of Esomeprazole (D961H)
      during repeated oral administration with and without co-administration of loxoprofen and the
      pharmacokinetic profile of loxoprofen during repeated oral administration with and without
      co-administration of Esomeprazole (D961H).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic profile of D961H during repeated administration with and without co-administration of loxoprofen and pharmacokinetic profile of loxoprofen during repeated administration with and without co-administration of D961H, assessing plasma conc.</measure>
    <time_frame>5-7 days after the last dose of study medication is given</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of D961H with and without coadministration of loxoprofen by assessment of adverse events, clinical laboratory tests (clinical chemistry, haematology, urinalysis and haemoccult test), ECG, blood pressure, pulse rate and body temperature</measure>
    <time_frame>5-7 days after the last dose of study medication is given</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole (D961H)</intervention_name>
    <description>20mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxoprofen</intervention_name>
    <description>60mg tablet</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Loxonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male

          -  Body Mass Index (BMI=weight/height2) 19-27 (kg/m2)

          -  Body weight 50-80 kg

        Exclusion Criteria:

          -  Past or present NSAIDs induced asthma, hepatic dysfunction, peptic ulcer or blood
             disorders

          -  Significant clinical illness from the 2 weeks preceding the pre-entry visit to the
             randomisation, as judged by the investigator(s) , eg, acute inflammatory disease which
             requires medical intervention

          -  Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease, as
             judged by the investigator(s), eg, sequelae of myocardial infarction, nephritis,
             hepatitis and cerebral infarction
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naotsugu Oyama, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michio Yagi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Pharmacology Clinical Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2008</study_first_posted>
  <last_update_submitted>March 11, 2009</last_update_submitted>
  <last_update_submitted_qc>March 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind - Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>male</keyword>
  <keyword>Japan</keyword>
  <keyword>Japanese</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

